GlobalData
ReportStore
 

 
Single User License: 
Buy Now Add to Cart
$2,000.00
Site License: 
Buy Now Add to Cart
$4,000.00
Global License: 
Buy Now Add to Cart
$6,000.00
 

Systemic Lupus Erythematosus - Drug Pipeline Analysis and Market Forecasts to 2015

Published: Dec-2009   Report Code: GDHCPRT016
Report Format: Electronic PDF
 
GlobalData, the industry analysis specialist’s new report, “Systemic Lupus Erythematosus – Drug Pipeline Analysis and Market Forecasts to 2015” is an essential source of information and analysis on the global systemic lupus erythematosus market. The report identifies the key trends shaping and driving the global systemic lupus erythematosus market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global systemic lupus erythematosus sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GlobalData’s team of industry experts.

Scope

  • The scope of the report includes:
  • Annualized global systemic lupus erythematosus market revenues data from 2000 to 2008, forecast forward for 7 years to 2015.
  • Geographies covered in this report include the US, the UK, Italy, Spain, Germany, France and Japan.
  • Pipeline analysis data providing a split across different phases by mechanism of action being developed and emerging trends. Key classes of mechanism of action include T and B cell modulators, Immunomodulators, Hormonal Agents, phosphodiesterase type 4inhibitor, Anti Alpha INF, Interleukin inhibitors and anti CD antigens.
  • Analysis of the current and future market competition in the global systemic lupus erythematosus market. Key market players covered are F. Hoffmann-La Roche Ltd (Genentech) , MedImmune, Bristol-Myers Squibb, GlaxoSmithKline, Human Genome Sciences, UCB S.A, Amgen and Biogen Idec.
  • Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs and implications for future market associated with systemic lupus erythematosus.

Reasons to Buy

  • The report will enhance your decision making capability in a more rapid and time sensitive manner. It will allow you to:
  • Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the global systemic lupus erythematosus market.
  • Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global systemic lupus erythematosus market in future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
  • What’s the next big thing in the global systemic lupus erythematosus market landscape? – Identify, understand and capitalize.